Ingredient of the Year
of the Year
LPLDL® is a naturally-occurring strain of the bacterial species Lactobacillus plantarum, originally isolated from tomatoes. Lactobacilli are common components of the human gut microbiome and have traditionally been used as probiotics. However, what makes LPLDL different from other Lactobacillus plantarum, is that this particular strain showcases exceptional improvements on the cardiovascular disease risk factors of LDL cholesterol and blood pressure.
Whereas high levels of cholesterol are commonly tackled by approaches that come with multiple undesirable side effects, LPLDL offers a scientific and naturally founded alternative to support improved cardiovascular health.
LPLDL was selected using OptiBiotix’s OptiScreen® proprietary technology platform from a collection of over 4,000 microbial candidates chosen for its excellent:
LPLDL is a next generation probiotic, rationally selected and optimised to harness the gut-liver axis for improved cardiovascular health. As well as reducing total and LDL cholesterol, LPLDL also demonstrated reductions in blood pressure whilst boosting HDL cholesterol.
An independent, double blind, randomised, placebo-controlled human study with a tablet containing LPLDL as the only active was performed by the University of Reading (United Kingdom) in 49 hypercholesterolemic adults. Volunteers consumed a daily dose of 4×109 CFU LPLDL or a placebo with results based on 12 weeks consumption.
LPLDL showed to be completely safe and well tolerated.
An independent, clinical study was carried out at the University of Pavia (Italy) in 40 adults with high normal blood pressure. Volunteers consumed 1 tablet of CholBiomeBP per day (containing 4×109 CFU LPLDL) with results based on 12 week’s consumption Vs baseline (pre-intervention) levels.
LPLDL is an industry recognised ingredient, and has been a runner up in multiple leading
industry awards within probiotic categories.
For more information on Lactobacillus plantarum LPLDL®, please contact us